When it comes to a clinical study to evaluate the therapeutic effect of Shivagutika treatment in patients with HIV, it was ...

The drug, in June, received FDA approval as the first twice-yearly pre-exposure prophylaxis (PrEP) option to reduce the risk ...

In Kenya, 1,378,457 people are living with HIV, with high prevalence reported among key population, including two out of ten ...

In a study of human immune cells infected with HIV, the virus that causes AIDS, scientists at Johns Hopkins Medicine say a molecule within HIV itself can be manipulated and amplified to force the ...

The US has approved lenacapavir for HIV prevention. However, experts worry that cuts to the health budget will "squander" the drug's chance of reducing infections.

The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS patients in the United States plans to phase them out next year.

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming infected with HIV. But big questions remain over the drug’s affordability.

HIV and AIDS are related, in that AIDS is the most advanced stage of an HIV infection, and therefore, the HIV virus causes both conditions. AIDS can also be called a "stage 3 HIV infection." ...

The five stages of infection are incubation, prodromal, illness, decline, and convalescence. Find out more here.

A phase 3 trial is now planned for the new formulation of lenacapavir, which could advance once-yearly medicines for HIV and other diseases.

Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of human immunodeficiency virus (HIV) infection in cisgender women. The efficacy of lenacapavir for preexposure ...